A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-017-3245-5

Related search